- Index
- 1 NOTE B1 Net sales
- 2 NOTE B2 Underlying raw material & energy costs
- 3 NOTE B3 Underlying EBITDA
- 4 NOTE B4 Underlying depreciation & amortization
- 5 NOTE B5 Underlying net financial charges
- 6 NOTE B6 Underlying income taxes
- 7 NOTE B7 Underlying profit from discontinued operations
- 8 NOTE B8 CAPEX
- 9 NOTE B9 Free Cash Flow
- 10 NOTE B10 Net working capital
- 11 NOTE B11 Underlying net debt
- 12 NOTE B12 CFROI
- 13 NOTE B13 Research & Innovation
In € million |
|
FY 2019 |
FY 2018 |
Research & development costs |
a |
(323) |
(297) |
Grants netted in research & development costs |
b |
26 |
25 |
Depreciation, amortization & impairments included in research & development costs |
c |
(83) |
(59) |
Capex in research & innovation |
d |
(70) |
(89) |
Research & innovation |
e = a-b-c+d |
(336) |
(352) |
Advanced Materials |
|
(157) |
(171) |
Advanced Formulations |
|
(94) |
(97) |
Performance Chemicals |
|
(25) |
(27) |
Corporate & Business Services |
|
(60) |
(58) |
Net sales |
f |
10,244 |
10,257 |
Advanced Materials |
|
4,512 |
4,385 |
Advanced Formulations |
|
2,846 |
3,057 |
Performance Chemicals |
|
2,879 |
2,808 |
Corporate & Business Services |
|
6 |
7 |
Research & innovation intensity |
g = -e/f |
3.3% |
3.4% |
Advanced Materials |
|
3.5% |
3.9% |
Advanced Formulations |
|
3.3% |
3.2% |
Performance Chemicals |
|
0.9% |
1.0% |
R&I effort decreased during 2019 as result of group wide operational cost reduction programs. Corporate R&I efforts were strongly redirected towards the material activities in preparation of the new G.R.O.W strategy.